Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity

Dezhi Xing, Daryl J. Murry, Mark S. Schmidt, Raymond Hohl, James B. Martins

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor has been associated with reduced implantable defibrillator shocks in several multicenter trials, suggesting an antiarrhythmic effect. Objective: The purpose of this study was to determine if lovastatin had an antiarrhythmic effect in a canine model of ischemic and inducible ventricular tachycardia (VT). Methods: Forty-seven α-chloralose anesthetized dogs underwent left anterior descending coronary occlusion. Three-dimensional activation mapping identified the mechanism of reinducible VT and the response to lovastatin (0.5 mg/kg IV). The endocardium was excised from foci and studied using standard microelectrode techniques with Tyrode's solution. Results: Lovastatin blocked focal VT in 8 of 13 dogs (P <.01) compared with only 1 of 12 saline-treated dogs with focal VT. Lovastatin had no effect on reentrant VT. Lovastatin did not alter the effective refractory period, arterial pressure, or percentage of ischemic electrograms. Effective plasma concentration of lovastatin hydroxy acid ranged from 21-157 ng/mL (0.8-3.7 × 10-7 M). In vitro rapid pacing, mostly with isoproterenol (5 × 10-7 M) superfusion, produced delayed afterdepolarizations and triggered activity (9 ± 2 action potentials). Lovastatin (10-7 M) produced no change in action potentials or delayed afterdepolarizations. However, triggered activity was attenuated to 2 ± 1 action potentials with lovastatin (P <.05, n = 13) but not with vehicle alone. Triggered activity returned to control after lovastatin washout (20 minutes) as well as with co-superfusion with mevalonic acid (10-6 M, n = 5). 2,2,6,6-Tetramethylpiperidine-N-oxyl, an antioxidant that enters tissues (10-3 M, n = 8), prevented triggered activity in a fashion similar to lovastatin. Conclusion: Lovastatin, in concentrations achievable in human plasma, specifically suppresses triggered activity and focal VT due to ischemia. A prenylated protein downstream from mevalonic acid may act as an antioxidant, producing the antiarrhythmic effect.

Original languageEnglish (US)
Pages (from-to)629-637
Number of pages9
JournalHeart Rhythm
Volume4
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Lovastatin
Ventricular Tachycardia
Action Potentials
Mevalonic Acid
Dogs
Antioxidants
Endocardium
Chloralose
Hydroxy Acids
Implantable Defibrillators
Coronary Occlusion
Microelectrodes
Isoproterenol
Multicenter Studies
Canidae
Shock
Arterial Pressure
Oxidoreductases
Ischemia

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Xing, Dezhi ; Murry, Daryl J. ; Schmidt, Mark S. ; Hohl, Raymond ; Martins, James B. / Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. In: Heart Rhythm. 2007 ; Vol. 4, No. 5. pp. 629-637.
@article{195724e3bba24d2198a3109532a5ef44,
title = "Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity",
abstract = "Background: Use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor has been associated with reduced implantable defibrillator shocks in several multicenter trials, suggesting an antiarrhythmic effect. Objective: The purpose of this study was to determine if lovastatin had an antiarrhythmic effect in a canine model of ischemic and inducible ventricular tachycardia (VT). Methods: Forty-seven α-chloralose anesthetized dogs underwent left anterior descending coronary occlusion. Three-dimensional activation mapping identified the mechanism of reinducible VT and the response to lovastatin (0.5 mg/kg IV). The endocardium was excised from foci and studied using standard microelectrode techniques with Tyrode's solution. Results: Lovastatin blocked focal VT in 8 of 13 dogs (P <.01) compared with only 1 of 12 saline-treated dogs with focal VT. Lovastatin had no effect on reentrant VT. Lovastatin did not alter the effective refractory period, arterial pressure, or percentage of ischemic electrograms. Effective plasma concentration of lovastatin hydroxy acid ranged from 21-157 ng/mL (0.8-3.7 × 10-7 M). In vitro rapid pacing, mostly with isoproterenol (5 × 10-7 M) superfusion, produced delayed afterdepolarizations and triggered activity (9 ± 2 action potentials). Lovastatin (10-7 M) produced no change in action potentials or delayed afterdepolarizations. However, triggered activity was attenuated to 2 ± 1 action potentials with lovastatin (P <.05, n = 13) but not with vehicle alone. Triggered activity returned to control after lovastatin washout (20 minutes) as well as with co-superfusion with mevalonic acid (10-6 M, n = 5). 2,2,6,6-Tetramethylpiperidine-N-oxyl, an antioxidant that enters tissues (10-3 M, n = 8), prevented triggered activity in a fashion similar to lovastatin. Conclusion: Lovastatin, in concentrations achievable in human plasma, specifically suppresses triggered activity and focal VT due to ischemia. A prenylated protein downstream from mevalonic acid may act as an antioxidant, producing the antiarrhythmic effect.",
author = "Dezhi Xing and Murry, {Daryl J.} and Schmidt, {Mark S.} and Raymond Hohl and Martins, {James B.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1016/j.hrthm.2006.12.051",
language = "English (US)",
volume = "4",
pages = "629--637",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "5",

}

Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity. / Xing, Dezhi; Murry, Daryl J.; Schmidt, Mark S.; Hohl, Raymond; Martins, James B.

In: Heart Rhythm, Vol. 4, No. 5, 01.05.2007, p. 629-637.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity

AU - Xing, Dezhi

AU - Murry, Daryl J.

AU - Schmidt, Mark S.

AU - Hohl, Raymond

AU - Martins, James B.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Background: Use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor has been associated with reduced implantable defibrillator shocks in several multicenter trials, suggesting an antiarrhythmic effect. Objective: The purpose of this study was to determine if lovastatin had an antiarrhythmic effect in a canine model of ischemic and inducible ventricular tachycardia (VT). Methods: Forty-seven α-chloralose anesthetized dogs underwent left anterior descending coronary occlusion. Three-dimensional activation mapping identified the mechanism of reinducible VT and the response to lovastatin (0.5 mg/kg IV). The endocardium was excised from foci and studied using standard microelectrode techniques with Tyrode's solution. Results: Lovastatin blocked focal VT in 8 of 13 dogs (P <.01) compared with only 1 of 12 saline-treated dogs with focal VT. Lovastatin had no effect on reentrant VT. Lovastatin did not alter the effective refractory period, arterial pressure, or percentage of ischemic electrograms. Effective plasma concentration of lovastatin hydroxy acid ranged from 21-157 ng/mL (0.8-3.7 × 10-7 M). In vitro rapid pacing, mostly with isoproterenol (5 × 10-7 M) superfusion, produced delayed afterdepolarizations and triggered activity (9 ± 2 action potentials). Lovastatin (10-7 M) produced no change in action potentials or delayed afterdepolarizations. However, triggered activity was attenuated to 2 ± 1 action potentials with lovastatin (P <.05, n = 13) but not with vehicle alone. Triggered activity returned to control after lovastatin washout (20 minutes) as well as with co-superfusion with mevalonic acid (10-6 M, n = 5). 2,2,6,6-Tetramethylpiperidine-N-oxyl, an antioxidant that enters tissues (10-3 M, n = 8), prevented triggered activity in a fashion similar to lovastatin. Conclusion: Lovastatin, in concentrations achievable in human plasma, specifically suppresses triggered activity and focal VT due to ischemia. A prenylated protein downstream from mevalonic acid may act as an antioxidant, producing the antiarrhythmic effect.

AB - Background: Use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor has been associated with reduced implantable defibrillator shocks in several multicenter trials, suggesting an antiarrhythmic effect. Objective: The purpose of this study was to determine if lovastatin had an antiarrhythmic effect in a canine model of ischemic and inducible ventricular tachycardia (VT). Methods: Forty-seven α-chloralose anesthetized dogs underwent left anterior descending coronary occlusion. Three-dimensional activation mapping identified the mechanism of reinducible VT and the response to lovastatin (0.5 mg/kg IV). The endocardium was excised from foci and studied using standard microelectrode techniques with Tyrode's solution. Results: Lovastatin blocked focal VT in 8 of 13 dogs (P <.01) compared with only 1 of 12 saline-treated dogs with focal VT. Lovastatin had no effect on reentrant VT. Lovastatin did not alter the effective refractory period, arterial pressure, or percentage of ischemic electrograms. Effective plasma concentration of lovastatin hydroxy acid ranged from 21-157 ng/mL (0.8-3.7 × 10-7 M). In vitro rapid pacing, mostly with isoproterenol (5 × 10-7 M) superfusion, produced delayed afterdepolarizations and triggered activity (9 ± 2 action potentials). Lovastatin (10-7 M) produced no change in action potentials or delayed afterdepolarizations. However, triggered activity was attenuated to 2 ± 1 action potentials with lovastatin (P <.05, n = 13) but not with vehicle alone. Triggered activity returned to control after lovastatin washout (20 minutes) as well as with co-superfusion with mevalonic acid (10-6 M, n = 5). 2,2,6,6-Tetramethylpiperidine-N-oxyl, an antioxidant that enters tissues (10-3 M, n = 8), prevented triggered activity in a fashion similar to lovastatin. Conclusion: Lovastatin, in concentrations achievable in human plasma, specifically suppresses triggered activity and focal VT due to ischemia. A prenylated protein downstream from mevalonic acid may act as an antioxidant, producing the antiarrhythmic effect.

UR - http://www.scopus.com/inward/record.url?scp=34247336883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247336883&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2006.12.051

DO - 10.1016/j.hrthm.2006.12.051

M3 - Article

VL - 4

SP - 629

EP - 637

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 5

ER -